The Centers for Medicare & Medicaid Services yesterday approved a Medicaid state plan amendment allowing Washington state to negotiate supplemental rebate agreements with drug makers based on value. CMS has approved similar state plan amendments for Oklahoma, Michigan and Colorado, but this is the first to focus on Hepatitis C drugs. Specifically, it allows the state to negotiate under a subscription model to pay a fixed annual amount to purchase an unrestricted supply of Hepatitis C drugs.

Related News Articles

Headline
The Government Accountability Office today named three new members to the Medicare Payment Advisory Commission through April 2023. They are: Wayne…
Headline
The Centers for Medicare & Medicaid Services yesterday released early stakeholder insights from its Accountable Health Communities Model. The model tests…
Headline
State Medicaid programs are reporting an uptick in enrollment compared with their fiscal year 2020 projections, due in part to the COVID-19 pandemic. The…
Headline
The Centers for Medicare & Medicaid Services May 7 issued a final rule that implements the standards governing health insurance issuers and the Health…
Headline
A federal district court in Washington, D.C., today heard oral argument in the AHA’s legal challenge to the Centers for Medicare & Medicaid Services’ final…
Headline
The Health Resources and Services Administration this week hosted webinars for health care providers on the agency’s COVID-19 Uninsured Program Portal. During…